Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy

被引:24
|
作者
Barbante Casella, Antonio Marcelo [1 ]
Berbel, Rodrigo Fabri [1 ]
Bressanim, Glaucio Luciano [2 ]
Malaguido, Marcus Rudolph [1 ]
Cardillo, Jose Augusto [3 ]
机构
[1] Univ Estadual Londrina, Dept Ophthalmol, Londrina, Brazil
[2] Inst Visao Cascavel, Dept Ophthalmol, Cascavel, Brazil
[3] Hosp Olhos Araraquara, Dept Ophthalmol, Araraquara, Brazil
关键词
Risk Factors; Central Serous Chorioretinopathy; Helicobacter Pylori; Treatment; Macula; DIFFUSE RETINAL EPITHELIOPATHY; PREVALENCE; INFECTION; THERAPY; PATHOGENESIS; ASSOCIATION; POPULATION; ADULTS; BRAZIL;
D O I
10.6061/clinics/2012(09)11
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES: The objective of this study was to evaluate the relationship between the treatment of Helicobacter pylori gastric infection and changes in best-corrected visual acuity and macular detachment in patients with chronic central serous chorioretinopathy. METHODS: Seventeen patients diagnosed with central serous chorioretinopathy were examined for gastric infection with Helicobacter pylori using the urease test and gastric biopsy. Helicobacter pylori-positive patients were treated with the appropriate medication. The response to therapy was monitored by evaluating the best-corrected visual acuity and optical coherence tomography. The data were analyzed using Student's t-test before and after treatment. RESULTS: Fourteen patients (15 eyes) aged 30-56 years (mean 43.4+/-8.3 years) were positive for Helicobacter pylori. Most of the positive patients had gastric symptoms (78.5%); one had bilateral central serous chorioretinopathy. The mean baseline best-corrected visual acuity was 20/98 (logMAR = 0.53+/-0.28). Three months after starting treatment with antibiotics, the serous detachment had resolved in 14 of 15 eyes, but two cases required laser treatment. The follow-up period ranged from 6 to 27 months. The mean final best-corrected visual acuity differed significantly from baseline. CONCLUSION: Our findings suggest that Helicobacter pylori infection may be present in many chronic central serous chorioretinopathy patients and that treatment for the infection may have a favorable effect on the outcome of chronic central serous chorioretinopathy. Due to the possibility of the spontaneous regression of chronic central serous chorioretinopathy and the high prevalence of the infection in the general population, prospective and masked clinical trials are necessary to confirm that treatment for Helicobacter pylori infection may benefit patients with chronic central serous chorioretinopathy.
引用
收藏
页码:1047 / 1052
页数:6
相关论文
共 50 条
  • [31] Treatment of central serous chorioretinopathy with mineralocorticoid receptor antagonists
    Cakir, B.
    Agostini, H.
    Lange, C.
    OPHTHALMOLOGE, 2019, 116 (02): : 189 - 200
  • [32] Diagnosis and Treatment of Central Serous Chorioretinopathy in Patients with Scleritis
    Tsai, Yu-Chien
    Chen, Yann-Guang
    Lee, Yueh-Chang
    Hwang, Yih-Shiou
    Hsieh, Yun-Hsiu
    MEDICINA-LITHUANIA, 2023, 59 (05):
  • [33] Current and emerging treatment options for central serous chorioretinopathy
    Borselli, Massimiliano
    Rossi, Costanza
    Chisari, Domenico
    Scalzo, Giovanna Carnovale
    Lucisano, Andrea
    Randazzo, Giorgio
    Mollace, Vincenzo
    Scorcia, Vincenzo
    Carnevali, Adriano
    EXPERT REVIEW OF OPHTHALMOLOGY, 2024, 19 (04) : 247 - 260
  • [34] FAMILIAL CENTRAL SEROUS CHORIORETINOPATHY
    van Dijk, Elon H. C.
    Schellevis, Rosa L.
    Breukink, Myrte B.
    Mohabati, Danial
    Dijkman, Greet
    Keunen, Jan E. E.
    Yzer, Suzanne
    Den Hollander, Anneke I.
    Hoyng, Carel B.
    de Jong, Eiko K.
    Boon, Camiel J. F.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (02): : 398 - 407
  • [35] Cadherin 5 is Regulated by Corticosteroids and Associated with Central Serous Chorioretinopathy
    Schubert, Carl
    Pryds, Anders
    Zeng, Shemin
    Xie, Yajing
    Freund, K. Bailey
    Spaide, Richard F.
    Merriam, John C.
    Barbazetto, Irene
    Slakter, Jason S.
    Chang, Stanley
    Munch, Inger C.
    Drack, Arlene V.
    Hernandez, Jasmine
    Yzer, Suzanne
    Merriam, Joanna E.
    Linneberg, Allan
    Larsen, Michael
    Yannuzzi, Lawrence A.
    Mullins, Robert F.
    Allikmets, Rando
    HUMAN MUTATION, 2014, 35 (07) : 859 - 867
  • [36] Risk Factors for Central Serous Chorioretinopathy: Multivariate Approach in a Case-Control Study
    Chatziralli, Irini
    Kabanarou, Stamatina A.
    Parikakis, Efstratios
    Chatzirallis, Alexandros
    Xirou, Tina
    Mitropoulos, Panagiotis
    CURRENT EYE RESEARCH, 2017, 42 (07) : 1069 - 1073
  • [37] Central serous chorioretinopathy: an update on pathogenesis and treatment
    Gemenetzi, M.
    De Salvo, G.
    Lotery, A. J.
    EYE, 2010, 24 (12) : 1743 - 1756
  • [38] Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis
    Kapoor, Kapil G.
    Wagner, Alan L.
    OPHTHALMIC RESEARCH, 2016, 56 (01) : 17 - 22
  • [39] Eplerenone for treatment of chronic central serous chorioretinopathy
    Fraenkel, Doris
    Suffo, Shady
    Langenbucher, Achim
    Seitz, Berthold
    Abdin, Alaa Din
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2021, 31 (04) : 1885 - 1891
  • [40] Treatment of central serous chorioretinopathy with topical NSAIDs
    Bahadorani, Sepehr
    Maclean, Kyle
    Wannamaker, Kendall
    Chu, Edward Rickie
    Gresores, Nathan
    Sohn, Jeong-Hyeon
    Diaz-Rohena, Roberto
    Singer, Michael A.
    CLINICAL OPHTHALMOLOGY, 2019, 13 : 1543 - 1548